Sign in
4

Changes in Ownership

Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000112

Chief Executive Officer sold 25,000 shares at an average $95.60 ($2,390,125)

  • Chief Executive Officer acquired 25,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Klein Lawrence Otto Chief Executive Officer 2026-11-02 Option exercise 10b5-1 +25,000 $7.80 $195,000 948,128 D: show line 1 in the form
Klein Lawrence Otto Chief Executive Officer 2026-11-02 Sale 10b5-1 −6,466 $94.77 $612,794 941,662 D: show line 2 in the form
Klein Lawrence Otto Chief Executive Officer 2026-11-02 Sale 10b5-1 −15,036 $95.64 $1,437,987 926,626 D: show line 3 in the form
Klein Lawrence Otto Chief Executive Officer 2026-11-02 Sale 10b5-1 −2,442 $96.70 $236,147 924,184 D: show line 4 in the form
Klein Lawrence Otto Chief Executive Officer 2026-11-02 Sale 10b5-1 −756 $97.45 $73,676 923,428 D: show line 5 in the form
Klein Lawrence Otto Chief Executive Officer 2026-11-02 Sale 10b5-1 −300 $98.40 $29,521 923,128 D: show line 6 in the form
Open-market sales · 25,000 sh · avg $95.60 · $2,390,125

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Klein Lawrence Otto Chief Executive Officer 2026-11-02 Option exercise · Employee Warrant (right to buy) 10b5-1 −25,000 1,503,513 D: show line 7 in the form
Loading xslF345X06/form4.xml…